S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
Log in

Orgenesis Stock Price, Forecast & Analysis (OTCMKTS:ORGS)

$3.37
+0.09 (+2.74 %)
(As of 11/13/2019 04:00 PM ET)
Add
Today's Range
$3.20
Now: $3.37
$3.38
50-Day Range
$3.01
MA: $3.68
$4.37
52-Week Range
$2.77
Now: $3.37
$6.32
Volume32,277 shs
Average Volume29,388 shs
Market Capitalization$54.40 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Orgenesis Inc is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolOTCMKTS:ORGS
Previous SymbolNASDAQ:ORGS
CUSIPN/A
Phone480-659-6404

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$54.40 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ORGS News and Ratings via Email

Sign-up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.


Orgenesis (OTCMKTS:ORGS) Frequently Asked Questions

What is Orgenesis' stock symbol?

Orgenesis trades on the OTCMKTS under the ticker symbol "ORGS."

How were Orgenesis' earnings last quarter?

Orgenesis Inc (OTCMKTS:ORGS) issued its quarterly earnings results on Monday, August, 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.26. The business earned $7.76 million during the quarter, compared to analysts' expectations of $6.38 million. View Orgenesis' Earnings History.

What price target have analysts set for ORGS?

2 equities research analysts have issued 1-year price objectives for Orgenesis' stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate Orgenesis' stock price to reach $9.00 in the next year. This suggests a possible upside of 167.1% from the stock's current price. View Analyst Price Targets for Orgenesis.

What is the consensus analysts' recommendation for Orgenesis?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orgenesis in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Orgenesis.

Has Orgenesis been receiving favorable news coverage?

News articles about ORGS stock have been trending very negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Orgenesis earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Orgenesis.

What other stocks do shareholders of Orgenesis own?

Who are Orgenesis' key executives?

Orgenesis' management team includes the folowing people:
  • Vered Caplan, Chairman of the Board, Chief Executive Officer, President; Chief Executive Officer of Orgenesis Maryland Inc. (Age 46)
  • Neil T. Reithinger CPA, Chief Financial Officer, Treasurer, Secretary (Age 46)
  • Sarah Ferber Ph.D., Chief Scientific Officer (Age 60)
  • Yaron Adler, Director (Age 44)
  • Hugues Bultot, Director
  • David Sidransky M.D., Director (Age 57)
  • Guy Yachin, Director (Age 47)

How do I buy shares of Orgenesis?

Shares of ORGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Orgenesis' stock price today?

One share of ORGS stock can currently be purchased for approximately $3.37.

How big of a company is Orgenesis?

Orgenesis has a market capitalization of $54.40 million. View Additional Information About Orgenesis.

What is Orgenesis' official website?

The official website for Orgenesis is http://www.orgenesis.com/.

How can I contact Orgenesis?

Orgenesis' mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 480-659-6404 or via email at [email protected]


MarketBeat Community Rating for Orgenesis (OTCMKTS ORGS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  36 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  80
MarketBeat's community ratings are surveys of what our community members think about Orgenesis and other stocks. Vote "Outperform" if you believe ORGS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORGS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel